CYP2A6 polymorphisms: Is there a role for pharmacogenomics in preventing coumarin-induced hepatotoxicity in lymphedema patients?

Pharmacogenomics

Volumn 8, Issue 2, 2007, Pages 151-158

  Farinola, Nicholas ^a   Piller, Neil B ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

Coumarin; Coumarin induced hepatotoxicity; CYP2A6 polymorphisms; CYP3A4 inducers; Lymphedema microarrays

Indexed keywords

3 HYDROXYCOUMARIN; ACETALDEHYDE; AFLATOXIN B1; ANTINEOPLASTIC AGENT; COUMARIN; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; NICOTINE; O HYDROXYPHENYLACETYLACETALDEHYDE; TAMOXIFEN; UMBELLIFERONE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BREAST CANCER; DETOXIFICATION; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; INCIDENCE; LIVER TOXICITY; LYMPHEDEMA; NONHUMAN; PHARMACOGENOMICS; SIDE EFFECT; TOBACCO DEPENDENCE;

ANIMALS; COUMARINS; HUMANS; LIVER DISEASES; LYMPHEDEMA; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

MUS; RATTUS;

EID: 33847042703     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.2.151     Document Type: Article

References (42)

1. Casley-Smith JR: Pre-ADEC response on adverse drug reactions to coumarin. Lymphoedema Association of Australia, Malyern, Australia (1995).
2. Felter SP, Vassallo JD, Carlton BD, Daston GP: A safety assessment ofcoumarin taking into account species-specificity of toxicokinetics. Food Chem. Taxicol. 44, 462-475(2006).
3. Farinola N, Piller N: Pharmacogenomics: its role in re-establishing coumarin as treatment for lymphedema. Lymphat. Res. Biol. 3(2), 81-86 (2005).
4. Casley-Smith JR: Benzopyrones in the treatment of lymphedema. Int. Angiol. 18(1), 31-41 (1995).
5. Badger C, Preston N, Seers K, Mortimer P: Benzo-pyrones for reducing and controlling lymphoedema of the limbs (Cochrane Review). In: The Cochrane Library, Issue 3. John Wiley & Sons, Ltd, Chichester, UK (2004).
6. Twycross R. Drug treatment for lymphoedema. In: Lympboedema. Twycross R, Jenns K, Todd J (Eds). Ausmed Publications, Melbourne, Australia, 244-270 (2003).
7. European Food Safety Authority: Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in Contacts with Food (AFC) on a request from the Commission related to coumarin. Question number EFSA-Q-2003-118. EFSA J. 104, 1-36 (2004).
8. Loprinzi CL, Kugler JW, Sloan JA et al.: Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. N. Engl. J. Med. 340, 346-350 (1999).
9. Lake BG: Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment. Food Chem. Toxicol. 37, 423-453 (1999).
10. Zhuo X, Gu J, Zhang Q-Y, Spink DC, Kaminsky LS, Ding X: Biotransformation of coumarin by rodent and human cytochromes P-450: metabolic basis of tissue-selective toxicity in olfactory mucosa of rats and mice. J Pharmacol. Exp. Ther. 288, 463-471 (1999).
11. Cottrell S. Oliver K, Lake BG, Powell CJ: Strain-specific enhancement or inhibition of coumarin hepatotoxicity in mice following pretreatment with two different liver enzyme-inducing agents. Fundam. Appl. Toxicol. 34(1), 47-55 (1996).
12. Lake BG, Evans JG, Chapuis F, Walters DG, Price RJ: Studies on the disposition, metabolism and hepatotoxicity of coumarin in the rat and Syrian hamster. Food Chem. Toxicol. 40(6), 809-823 (2002).
13. Miles JS, McLaren AW, Forrester LM, Glancey MJ, Lang MA, Wolf CA: Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem. J. 267(2), 365-371 (1990).
14. Hadidi H, Zahlsen K, Idle JR, Cholerton S: A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. Food Chem. Toxicol. 35(9), 903-907 (1997).
15. Born SL, Caudill D, Filter KL, Purdon MP: Identification of the cytochromes P450 that catalyze coumarin 3,4-epoxidation and 3-hydroxylation. Drug Metab. Dispos. 30(5), 483-487 (2002).
16. Goeger DE, Hsie AW, Anderson KE: Co-mutagerilcity of coumarin (1,2-benzopyrone) with aflatocin B1 and human liver S9 in mammalian cells. Food Chem. Toxicol. 37, 581-589 (1999).
17. Desai PB, Nallani SC, Sane RS et al.: Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab. Dispos. 30(5),608-612 (2002).
18. Hukkanen J, Mantyla M, Kangas L et al.: Expression of cytochrome P450 genes encoding enzymes active in the metabolism of tamoxifen in human uterine endometrium. Pharmacol. Toxicol. 82(2), 93-97 (1998).
19. Casley-Smith JR: Response on proposed de-registration of Lodema tablets. Lymphoedema Association of Australia, Malvern, Australia (1999).
20. Pasanen M, Rannala Z, Tooming A, Sotaniemi EA, Pelkonen O, Rautio A: Hepatitis A impairs the function of human hepatic CYP2A6 in vivo. Toxicology 123 (3), 177-184 (1997).
21. Dalekos GN, Obermayer-Straub P, Bartels M et al.: Cytochrome P450 2A6: a new hepatic autoantigen in patients with chronic hepatitis C virus infection. J. Hepatol. 39(5), 800-806 (2003).
22. Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab. Rev. 35(2-3), 99-106 (2003).
23. Raunio, H, Rautio A, Gulisten H, Pelkonnen O: Polymorphisms of CYP2A6 and its practical consequences. Br. J Clin. Pharmacol. 52, 357-363 (2001).
24. Inoue K, Yamazaki H, Shimada T. CYP246 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians. Arch. Tadcol. 73 (10-11), 532-953, (2000).
25. Fernandez-Salguero P, Hoffman SM, Cholerton S et al.: A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am. J. Hum. Genet. 57, 651-660 (1995).
26. Haberi M, Anwald B, Klein K et al.: Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet. Genomics 15(9), 609-624 (2005).
27. Nunoya K-I, Yokoi T, Kimura K et al.: A new deleted allele In the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride 3(SM-12502). Pharmacogenetics 8, 239-249 (1998).
28. Nunoya K-I, Yokol T, Kimura K et al.: A new CYP24A gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride in humans. J Pharmacol. Exp. Ther. 289, 437-442 (1999).
29. Nakajima M, Kwon J-T, Tanaka N et al.: Relationship between interindividual differences In nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin. Pharmacol. 77mr. 69, 72-78 (2001).
30. Kwon J T, Nakajima M, Chal S et al.: Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics 11, 317-323 (2001).
31. Yoshida R, Nakajima M, Watanabe Y, Kwon JT, Yokoi T: Genetic polymorphisms in human CYP2A6gene causing impaired nicotine metabolism. Br. J Clin. Pharmacol. 54(5), 511-517 (2002).
32. Nakajima M, Yokoi T. Interindividual variability in nicotine metabolism: C -oxidation and glucuronidation. Drug Metab. Pharmacokinet. 20(4), 227-235 (2005).
33. Oscarson M, McLellan RA, Asp V etal.: Characterisation of a novel CYP2A7/ CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum. Mutat. 20, 275-283 (2002).
34. Van Iersel MLPS, Henderson CJ, Walters DG, Price RJ. Wolf CR, Lake BG: Metabolism of [3-14C] coumarin by human liver microsomes. Xenobiotica 24(8), 795-803 (1994).
35. Sellers EM, Kaplan HL, Romach MK, Tyndale RF: Inhibition of CYP2A6 decreases smoking. Clin. Pharmacol. Ther. 63, 153 (2000).
36. Ingelman-Sundberg M: Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci 25(4), 193-200 (2004).
37. Nakajima M, Yamagishi S, Yamamoto H, Yamamoto T, Kuroiwa Y, Yokoi T. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clin. Pharmacol. Ther. 67(1), 57-69 (2000).
38. Nakajima M, Yoshida R, Fukami T, McLeod HL, Yokot T: Novel human CYP2A6 alleles confound gene deletion analysis. FEBS Lett. 569, 75-81 (2004).
39. Burian M, Freundenstein J, Tegtmeier M, Naser-Hijazi B, Hernneicke-von Zepelin HH, Legrum W. Single copy of variant CYP2A6 alleles does not confer susceptibility to liver dysfunction in patients treated with coumarin. Int. J Clin. Pharmacol. Ther. 41(4). 141-147 (2003).
40. Kiyotani K, Yamazaki H, Fujieda M et al.: Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter moon (CITN6*6). Pharmacogenetics 13(11), 689-695 (2003).
41. Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, Ingelman-Sundberg M: Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem. Biophys. Res. Commun. 284(2), 455-460 (2001).
42. Yoshida R, Nakajima M, Nishimura K, Tokudome S, Kwon JT, Yokoi T: Effects of polymorphism in promoter region of human CFP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin. Pharmacol. Ther. 74(1), 69-76 (2003).